Literature DB >> 6646243

Selective inhibition of monoamine oxidase in monoaminergic neurons in the rat brain.

A L Ask, I Fagervall, S B Ross.   

Abstract

The prevention by six reversible and selective monoamine oxidase-A (MAO-A) inhibitors (alpha-ethyl-tryptamine, harmaline, 4-methoxyamphetamine, amiflamine [FLA 336(+)], N-desmethylamiflamine [FLA 788(+)] and N,N-desmethylamiflamine [FLA 668(+)] of the phenelzine-induced irreversible MAO inhibition in the rat brain was examined. By using crude synaptosome preparations of hypothalamus and striatum incubated with low substrate concentrations of 14C-serotonin (1 X 10(-7) M), 14C-noradrenaline (2.5 X 10(-7) M) and 14C-dopamine (2.5 X 10(-7) M) in the absence and presence of selective amine uptake inhibitors (alaproclate, maprotiline and amfonelic acid, respectively), it was possible to determine the deaminating activities inside and outside the specific aminergic synaptosomes. Thus, with this technique the protection of MAO by the reversible inhibitors administered orally 1 h prior to the subcutaneous injection of phenelzine against the phenelzine effect could be determined inside and outside the specific aminergic neurons. It was found that alpha-ethyltryptamine, 4-methoxyamphetamine and particularly amiflamine and FLA 788(+) were more potent inside than outside the serotonergic neurons. FLA 668(+) was a selective inhibitor of noradrenergic MAO, to which also 4-methoxyamphetamine, amiflamine and FLA 788(+), but not alpha-ethyltryptamine had some preference. Harmaline had no certain preference for MAO in any of the aminergic neurons. At high doses of FLA 668(+) a preference for dopaminergic MAO was observed. Since pretreatment of the rats with norzimeldine or desipramine antagonized the preferences for serotonergic or noradrenergic MAO, it is plausible to conclude that the compounds showing these preferences are accumulated in the neurons by the membranal uptake systems.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6646243     DOI: 10.1007/BF00497011

Source DB:  PubMed          Journal:  Naunyn Schmiedebergs Arch Pharmacol        ISSN: 0028-1298            Impact factor:   3.000


  14 in total

1.  Antagonism between harmaline and longacting monoamine oxidase inhibitors concerning the effect on 5-hydroxytryptamine and norepinephrine metabolism in the brain.

Authors:  A PLETSCHER; H BESENDORF
Journal:  Experientia       Date:  1959-01-15

2.  The interaction between reversible and irreversible monoamine oxidase inhibitors.

Authors:  A HORITA; W R McGRATH
Journal:  Biochem Pharmacol       Date:  1960-06       Impact factor: 5.858

3.  Selective monoamine oxidase inhibitors. 1. Compounds related to 4-aminophenethylamine.

Authors:  L Florvall; A L Ask; S O Ogren; S B Ross
Journal:  J Med Chem       Date:  1978-01       Impact factor: 7.446

4.  Interactions of bretylium and other drugs on guinea-pig atria: evidence for inhibition of neuronal monoamine oxidase by bretylium.

Authors:  R F Furchgott; P S Garcia; A R Wakade; P Cervoni
Journal:  J Pharmacol Exp Ther       Date:  1971-11       Impact factor: 4.030

5.  p-Methoxyamphetamine, a potent reversible inhibitor of type-A monoamine oxidase in vitro and in vivo.

Authors:  A L Green; M A El Hait
Journal:  J Pharm Pharmacol       Date:  1980-04       Impact factor: 3.765

6.  Uptake and metabolism of catecholamines in rat brain synaptosomes: studies on the contribution of monoamine oxidase.

Authors:  S Urwyler; J P von Wartburg
Journal:  Biochem Pharmacol       Date:  1981-10       Impact factor: 5.858

7.  (+)-4-Dimethylamino-2,alpha-dimethylphenethylamine (FLA 336(+)), a selective inhibitor of the A form of monoamine oxidase in the rat brain.

Authors:  A L Ask; K Högberg; L Schmidt; H Kiessling; S B Ross
Journal:  Biochem Pharmacol       Date:  1982-04-01       Impact factor: 5.858

8.  Interactions between reserpine and various compounds on the accumulation of [14C] 5-hydroxytryptamine and [3H]noradrenaline in homogenates from rat hypothalamus.

Authors:  S B Ross
Journal:  Biochem Pharmacol       Date:  1979-04-01       Impact factor: 5.858

9.  Structural requirements for uptake into serotoninergic neurones.

Authors:  S B Ross; A L Ask
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1980-04

10.  Inhibition of 3H-dopamine accumulation in reserpinized and normal rat striatum.

Authors:  S B Ross; D Kelder
Journal:  Acta Pharmacol Toxicol (Copenh)       Date:  1979-05
View more
  14 in total

1.  Inhibition of 5-hydroxytryptamine accumulation and deamination by substituted phenylalkylamines in hypothalamic synaptosomes from normal and reserpine-pretreated rats.

Authors:  A L Ask; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1987-12       Impact factor: 3.000

2.  Selective inhibition by 4,alpha-dimethyl-m-tyramine (H77/77) and 4-methyl-alpha-ethyl-m-tyramine (H75/12) of the monoamine oxidase within serotonergic and noradrenergic neurons in the rat brain.

Authors:  I Fagervall; D Kelder; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-08       Impact factor: 3.000

3.  Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids.

Authors:  I Thiblin; A Finn; S B Ross; C Stenfors
Journal:  Br J Pharmacol       Date:  1999-03       Impact factor: 8.739

4.  Locus coeruleus neurons show reduced alpha 2-receptor responsiveness and decreased basal activity in spontaneously hypertensive rats.

Authors:  G Engberg; L Oreland; P Thorén; T Svensson
Journal:  J Neural Transm       Date:  1987       Impact factor: 3.575

5.  The inhibition of the cage-leaving response--a model for studies of the serotonergic neurotransmission in the rat.

Authors:  L Rényi; T Archer; B G Minor; B Tandberg; A Fredriksson; S B Ross
Journal:  J Neural Transm       Date:  1986       Impact factor: 3.575

6.  Relation between brain monoamine oxidase (MAO) activity and the firing rate of locus coeruleus neurons.

Authors:  L Oreland; G Engberg
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1986-07       Impact factor: 3.000

7.  Inhibition of monoamine oxidase in 5-hydroxytryptaminergic neurones by substituted p-aminophenylalkylamines.

Authors:  A L Ask; I Fagervall; L Florvall; S B Ross; S Ytterborn
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

8.  Effects of a monoamine oxidase A inhibitor, FLA 668 (+) on the adrenergic mechanisms of the dog saphenous vein.

Authors:  M M Caramona; J V Esplugues; W Osswald
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1985-11       Impact factor: 3.000

9.  Release of 3H-5-hydroxytryptamine by amiflamine and related phenylalkylamines from rat occipital cortex slices.

Authors:  A L Ask; I Fagervall; R B Huang; S B Ross
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-06       Impact factor: 3.000

10.  Increased total activity in the rat after L-tryptophan plus the monoamine oxidase-A inhibitor amiflamine but not after L-tryptophan plus clorgyline.

Authors:  T Archer; C J Fowler; A Fredriksson; T Lewander; O Magnusson; B Mohringe; U Söderberg
Journal:  Br J Pharmacol       Date:  1985-07       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.